Social Media Listening report on Aliqopa drug from Bayer healthcare Pharmaceuticals got US FDA approval for Relapsed/Refractory Follicular Lymphoma
Research Study Background
On 14th September 2017 FDA approves Bayer’s Aliqopa (copanlisib) for the treatment of Relapsed or Refractory Follicular Lymphoma. Aliqopa is a Kinase inhibitor that works against PI3K-alpha and PI3K-delta isoforms expressed in malignant B cells. Aliqopa got accelerated approval was on the basis of Phase-2 CHRONOS-1 study where Copanlisib has shown Overall Response Rate (59%) in patients with relapsed Follicular Lymphoma. Formerly FDA had approved copanlisib profligate track designation in Follicular Lymphoma as well as Orphan Drug designation for the treatment of patients with Follicular Lymphoma
Findings:
Sentiment Analysis on Aliqopa Drug Approval
Positive: Aliqopa approval was quoted as an Impressive breakthrough - “Bayer’s Aliqopa Wins Accelerated Approval”- Pharmacist (NYRXMAN)
Neutral: Majority of healthcare practitioners and patients were either neutral or positive about the approval, efficacy and found sharing the information on social media platform- “FDA approves Copanlisib (PI3Ki) for relapsed follicular lymphoma”- HCP (DRANASYOUNES)
Contact us for qualitative social media monitoring and social media intelligence research/reports.